Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Neoplasms 41Breast Neoplasms 40Lung Neoplasms 25Carcinoma, Non-Small-Cell Lung 20Colorectal Neoplasms 19Uterine Cervical Neoplasms 13Prostatic Neoplasms 13Head and Neck Neoplasms 11Carcinoma, Hepatocellular 11Pancreatic Neoplasms 10Melanoma 10Ovarian Neoplasms 9Neoplastic Cells, Circulating 7Myelodysplastic Syndromes 7Glioma 7Esophageal Neoplasms 7Endometrial Neoplasms 7Brain Neoplasms 7Sarcoma 6Multiple Myeloma 6Gastrointestinal Neoplasms 6Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Leukemia, Myeloid, Acute 5Disease 5Colonic Neoplasms 5Uveal Melanoma 4Skin Neoplasms 4Neoplasm, Residual 4

Interventions

Cyclophosphamide 8Rituximab 5fludarabine 4Vincristine 4Prednisone 4Doxorubicin 4fludarabine phosphate 3Tacrolimus 3Mycophenolic Acid 3Etoposide 3Busulfan 3venetoclax 2entrectinib 2atezolizumab 2alectinib 2acalabrutinib 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Bortezomib 2trametinib 1pertuzumab 1pembrolizumab 1obinutuzumab 1liposomal doxorubicin 1isatuximab 1ibrutinib 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × Blood Specimen Collection × 1 year × Clear all
NCT01728402 2026-02-17

Pathogenesis of Hematologic Malignancies

OHSU Knight Cancer Institute

Enrolling by invitation
5,000 enrolled
LymphoidMyeloid

Lymphoproliferative Disorders, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡